Inovio Pharmaceuticals $INO Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up INOVIO PHARMACEUTICALS, INC. ($INO). Last filing: 8-K (5.03 Amendments to Articles or Bylaws; Change in Fiscal Year), 2026-10-06. 13 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $65K (FY2025). Experience: revenue down 70.0% on the year, down 56.2% a year over 4 years; operating margin -132871.3%, down from -51616.9%. Soundness: equity 32.4% of assets, return on equity -352.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4K and $64K next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3K to $79K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -132871.3% against a -3.8% median; growth -70.0% against 13.7%.
Cash
| Cash flow (op · inv · fin · free) | −$89M · $14M · $53M · −$89M |
| Investment book (cash · short · long) | $44M · $14M · — · current ratio 1.40 · unrealized −$1M |
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $0M |
| Revenue, on the year | −70.0% |
| Revenue, a year over the record | −56.2% |
| Operating margin | −132871.3% |
| Operating margin, prior year | −51616.9% |
| Net margin | −130000.0% |
| Research and development | $54M · 82957.4% of revenue |
| Total debt | — |
| Equity of assets | 32.4% |
| Return on equity | −352.5% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-1.81 |
| Book value per share | $0.51 |
| Revenue per share | $0.00 |
| Shares outstanding | 46,886,413 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborInovio Pharmaceuticals sails as: Weathered boat
Health watch · 12 monthsquiet · none of the watched events filed
No growth figure to set the speed.
🌊 Visit the Bay →- operating cash flow was negative (-$88.6M in FY2025)
- revenue is hard to predict: its 80% range is ±89%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-10-06 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-08-12
- 8-K · 2026-07-31 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 8-K · 2026-07-29 · 2.02 Results of Operations and Financial Condition
- 8-K · 2026-05-20 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company